Privia Health Group (PRVA) Projected to Release Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Privia Health Group to post earnings of $0.0683 per share and revenue of $597.7370 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Privia Health Group Stock Performance

PRVA stock opened at $23.79 on Wednesday. The stock’s 50 day moving average price is $24.56 and its 200 day moving average price is $23.36. The firm has a market cap of $3.00 billion, a P/E ratio of 148.70, a PEG ratio of 1.88 and a beta of 0.85. Privia Health Group has a 1 year low of $19.08 and a 1 year high of $28.82.

Insider Activity at Privia Health Group

In other Privia Health Group news, CEO Parth Mehrotra sold 105,439 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the completion of the sale, the chief executive officer owned 450,004 shares of the company’s stock, valued at approximately $10,147,590.20. The trade was a 18.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Matthew Shawn Morris sold 88,110 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the transaction, the director owned 76,651 shares in the company, valued at approximately $1,941,569.83. This trade represents a 53.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 452,357 shares of company stock worth $11,436,655. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Privia Health Group

Several large investors have recently made changes to their positions in the business. Elo Mutual Pension Insurance Co purchased a new stake in Privia Health Group during the 4th quarter worth $478,000. Vanguard Personalized Indexing Management LLC raised its position in Privia Health Group by 5.9% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after purchasing an additional 903 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Privia Health Group in the fourth quarter valued at about $362,000. Smartleaf Asset Management LLC lifted its stake in shares of Privia Health Group by 16.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 14,395 shares of the company’s stock worth $343,000 after purchasing an additional 1,997 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in shares of Privia Health Group in the second quarter worth about $329,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Zacks Research cut shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Evercore set a $26.00 price target on shares of Privia Health Group in a report on Wednesday, April 8th. Finally, Citigroup reissued a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.